Glaukos Holds Lead In Microinvasive Glaucoma Surgery
Glaukos has emerged as the leader in microinvasive glaucoma surgery, a new treatment for the multibillion-dollar market. CEO Tom Burns lays out his vision for his company and for the future of MIGS.
You may also be interested in...
Glaukos' Micro-Bypass Stents Work As First-Line Glaucoma Therapy
Results of a 101-patient randomized clinical trial show that implantation of two iStent Trabecular Micro-Bypass stents is a viable initial treatment option, comparable to topical ocular hypotensive medications, in patients with newly diagnosed primary open-angle glaucoma.
Minimally Invasive Glaucoma Device Guidance Finalized
The "leap frog guidance” outlines clinical and non-clinical testing recommendations for the nascent field of minimally invasive glaucoma surgical (MIGS) devices. It closely matches a February draft guidance.
Finding The Fit For Ophthalmology In The New Pfizer
The merger of Pfizer and Allergan might raise broader questions about the fairness – or long-term viability – of the corporate tax code in the US. But it also has generated some angst over Allergan’s future as a stalwart in ophthalmology.